Education
About Us
Working with TipRanks
Follow Us
Applied Therapeutics Inc (APLT)
NASDAQ:APLT
APLT Stock Chart & Stats
$0.10
-$0.07(-8.39%)
At close: 4:00 PM EST
$0.10
-$0.07(-8.39%)
Day’s Range― - ―
52-Week Range$0.09 - $1.50
Previous CloseN/A
Volume3.84M
Average Volume (3M)17.54M
Market Cap
$14.86M
Enterprise Value$5.42M
Total Cash (Recent Filing)$11.95M
Total Debt (Recent Filing)$2.50M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Mar 13, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding144,300,670
10 Day Avg. Volume47,414,159
30 Day Avg. Volume17,542,089
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.10
Price to Sales (P/S)262.57
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue5.42
Enterprise Value/Gross Profit-0.19
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$0.25Price Target Upside150.00% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AcquisitionAcquisition by Cycle Group could provide a fresh start for govorestat, bringing new capital and strategic direction that may accelerate development or attract partners.
Board DecisionUnanimous board approval after a review of strategic alternatives signals decisive governance action to pursue options intended to maximize shareholder value.
Contingent Milestone PaymentsEntitlement to potential additional payments tied to achievement milestones creates upside for shareholders if development or commercial goals are met under the transaction.
Bears Say
Commercialization CapabilityStatement that the company is not positioned to advance govorestat to commercialization increases the risk of development delays or the need to secure a new developer.
Operational And Leadership DisruptionSignificant workforce reductions and the executive chairman's departure suggest operational strain and leadership disruption that could impede program execution and cash preservation efforts.
Regulatory And Clinical UncertaintyUnresolved questions on disease biology, acceptable surrogate endpoints, pivotal trial design, and carcinogenicity testing create significant uncertainty around any approval pathway.
Applied Therapeutics News
APLT FAQ
What was Applied Therapeutics Inc’s price range in the past 12 months?
Applied Therapeutics Inc lowest stock price was $0.09 and its highest was $1.50 in the past 12 months.
What is Applied Therapeutics Inc’s market cap?
Applied Therapeutics Inc’s market cap is $14.86M.
When is Applied Therapeutics Inc’s upcoming earnings report date?
Applied Therapeutics Inc’s upcoming earnings report date is Mar 13, 2026 which is in 35 days.
How were Applied Therapeutics Inc’s earnings last quarter?
Applied Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.141 by $0.011.
Is Applied Therapeutics Inc overvalued?
According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued.
Does Applied Therapeutics Inc pay dividends?
Applied Therapeutics Inc does not currently pay dividends.
What is Applied Therapeutics Inc’s EPS estimate?
Applied Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Applied Therapeutics Inc have?
Applied Therapeutics Inc has 144,300,670 shares outstanding.
What happened to Applied Therapeutics Inc’s price movement after its last earnings report?
Applied Therapeutics Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.141. Following the earnings report the stock price went down -70.33%.
Which hedge fund is a major shareholder of Applied Therapeutics Inc?
Currently, no hedge funds are holding shares in APLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
APLT Stock 12 Month Forecast
Average Price Target
$0.25
▲(150.00% Upside)
Technical Analysis
Ownership Overview
3.10% Insiders
13.11% Mutual Funds
0.27% Other Institutional Investors
77.83% Public Companies and
Individual Investors